Eisai and Biogen’s new Alzheimer’s treatment, lecanemab, received a green light from UK regulators, marking a significant advance in treating early-stage Alzheimer’s disease.
In a promising advancement, scientists from the University of North Carolina at Chapel Hill and Emory University have developed a novel drug delivery system using synthetic amyloid beta (Aβ) peptides.
Eli Lilly may be on the brink of reshaping the pharma landscape, with its treatments, Mounjaro (tirzepatide) for obesity and the highly anticipated donanemab for early symptomatic Alzheimer’s disease.
Biogen’s stance at the upcoming AD/PD 2024 International Conference on Alzheimer’s disease and Parkinson’s disease will demonstrate its future plans for treating Alzheimer’s, following the discontinuation of Aduhelm (aducanumab), its anti-amyloid beta...
Researchers at the UK Dementia Research Institute have developed a new form of deep brain stimulation that does not require surgery and could provide an alternative treatment option for debilitating brain diseases such as Alzheimer’s.
Vaxxinity has announced the publication of its phase 2 clinical trial data for UB-311, stating that the treatment was safe, well-tolerated and demonstrated a trend for slowing cognitive decline in mild Alzheimer's disease (AD).
Alnylam Pharmaceuticals has announced positive interim results for the ongoing single ascending dose portion of the phase 1 study of ALN-APP, an investigational RNAi therapeutic targeting amyloid precursor protein (APP) in development for the treatment...
The first and only approved anti-amyloid Alzheimer's Disease (AD) treatment shown to reduce the rate of disease progression and slow cognitive impairment has been granted approval by the FDA.
Axol Bioscience Ltd, a pluripotent stem cell technology provider for drug discovery, has signed an exclusive agreement with StrataStem to access and commercialize its extensive collection of Alzheimer’s Disease (AD) patient samples.
The antibody drug donanemab, developed by the pharma giant Eli Lilly, has met all of its goals in a phase 3 trial for slowing cognitive decline in people with Alzheimer’s disease.
As part of a $1 billion deal forged in 2020, Biogen has exercised the option to license a treatment candidate for Alzheimer’s disease developed by the US biotech company Denali Therapeutics. The engineered antibody drug is designed to cross into the brain...
Eisai has submitted marketing authorization applications for lecanemab in Europe and Japan as it builds up its global plans for the Alzheimer’s drug, which was approved in the US earlier this month.
With Eisai and Biogen’s Alzheimer’s drug Leqembi (lecanemab) approved by the US Food and Drug Administration (FDA) last week, Eisai has revealed more details on its rollout plans for the drug.
On Friday (Jan 6), the US Food and Drink Administration (FDA) granted a licence for another anti-amyloid drug – lecanemab – to treat Alzheimer’s disease.
The phase 3 trial results for lecanemab and gantenerumab presented at the Clinical Trials on Alzheimer’s Disease (CTAD) conference demonstrate why optimal treatment of Alzheimer’s will require drugs that do more than clear amyloid plaques, says the Alzheimer’s...
Roche announced yesterday that Phase 3 studies for its Alzheimer’s drug gantenerumab failed to meet the primary endpoint of slowing clinical decline. Although disappointed, Alzheimer’s associations are hopeful there is still a lot that can be learned...
Acumen Pharmaceuticals believes ACU193 – the first clinical-stage monoclonal antibody that selectively targets toxic soluble amyloid beta oligomers (AβO) – offers the promise of an effective treatment with a better safety profile than other Alzheimer's...
The WHO has set out a new blueprint for dementia research: outlining the potential of precision medicine, repurposed drugs and revamped clinical trials. “Addressing dementia is one of the greatest health challenges of our generation,” says the organization.
The recent lecanemab trial read-out will have a sizeable impact on the path forward for other biopharma’s developing treatments for Alzheimer’s disease, says the chief executive of a company developing investigational therapies for rare peripheral amyloid...
An investigational Alzheimer's drug made by Eisai Co Ltd and Biogen slowed cognitive and functional decline in a trial involving a large group of patients in the early stages of the disease.
The pharmaceutical company has inked a strategic collaboration with the drug discovery firm, centering on uncovering novel targets in Alzheimer’s disease.
The Cell and Gene Therapy Catapult (CGT Catapult) and the UK Dementia Research Institute (UK DRI) have announced a collaboration to accelerate clinical development of adeno-associated virus (AAV) based gene therapies for dementia.
A survey from Spherix gathered reactions from US neurologists after the US Centers for Medicare & Medicaid Services (CMS) announced its National Coverage Determination for monoclonal antibodies against amyloid for the treatment of Alzheimer’s.
Biogen will ‘substantially eliminate’ commercial infrastructure for Alzheimer’s drug Aduhelm and take additional cost-reduction measures, the company announced as it released its Q1 2022 results this morning.
Prothena has been granted fast track designation from the US Food and Drug Administration (FDA) to develop a next-generation treatment for Alzheimer’s disease, PRX012.
Biogen has withdrawn its Marketing Authorization Application for Aduhelm (aducanumab) for the treatment of the early stages of Alzheimer’s disease in the EU.
Biogen's Phase 4 trial for Aduhelm – required by the FDA as part of last year's accelerated approval of the Alzheimer’s drug – will start screening patients in May.
Biogen has announced new Phase 3 data showing that, after nearly 2.5 years of treatment, Aduhelm continued to reduce two key Alzheimer’s disease pathologies.
Finnish company, Biovian Oy, has been engaged by a South Korea biotechnology company to carry out process development and manufacturing of an AAV-based innovative drug candidate.
Biogen has started the process of laying off some US staff, following the less than optimal rollout of its Alzheimer’s disease drug, approved by the FDA in June 2021.
Biogen releases further details on how its Phase 4 post-marketing confirmatory study for Alzheimer’s drug, Aduhelm, will run: including increased enrolment and enhanced efforts to encourage diversity.
This week the US Centers for Medicare & Medicaid Services (CMS) has announced a long-awaited proposal for Aduhelm coverage: proposing it would only cover the recently approved Alzheimer’s Drug for people in qualifying clinical trials. This could have...
Lecanemab, an investigational anti-amyloid beta (Aβ) protofibril antibody for the treatment of early Alzheimer's disease, has been granted Fast Track designation by the US Food and Drug Administration (FDA).
As of January 1, 2022, Biogen will cut the price of its Alzheimer’s drug Aduhelm (aducanumab-avwa) in half: saying too many patients are not currently being offered the choice of the drug due to financial considerations.
Biogen will ask the European Medicines Agency (EMA) to re-examine its Alzheimer’s drug application, following the agency’s recommendation to refuse authorization of the drug in the EU.
Emulate, Inc recently launched the Zoë-CM2 Culture Module, a second-generation Zoë instrument core to its ‘Organ-on-a-Chip’ based Human Emulation System.
Biogen says it is disappointed with feedback received from a European Medicines Agency committee on its aducanumab Marketing Authorization Application: but pledges to continue to engage with the regulator as it considers its next steps.
EIT Health and Biogen have launched the ‘neurotechprize’ to help develop promising technology from all over the world that looks to address Alzheimer’s disease (AD).
The race is on: Eli Lilly has begun the application for the approval of its Alzheimer's disease (AD) treatment in the US, potentially setting it up against rival Biogen's recently approved Aduhelm.
Previously a series of unsuccessful clinical trials for treatments, combined with the high costs of R&D in the area, led to declining interest in dementia research but a new publication from the WHO notes a definite uptick in the funding of such work...
There is “some way to go” before UnitedHealth Group has the clarity to make a coverage decision on Biogen’s Alzheimer’s disease drug Aduhelm, according to the CEO of the healthcare company.
Data presented by Prothena at AAIC on two of its Alzheimer’s disease programs suggests PRX012, its next generation anti-amyloid beta (Aβ) antibody, can clear two types of Aβ plaque in brain tissue, and that its AD vaccine program can simultaneously target...
Eli Lilly and Company and Banner Alzheimer’s Institute have announced a strategic research collaboration as part of the planned Phase 3 study for donanemab in participants at risk from cognitive and functional decline related to Alzheimer’s disease.